抑亢汤联合二甲双胍治疗多囊卵巢综合征的临床疗效及对患者性激素、体重指数的影响

陈祥艳; 胡欣欣; 徐甜甜; 柳侠平; 李鹏; 陈苗苗; 孙云

doi:10.16766/j.cnki.issn.1674-4152.004087

抑亢汤联合二甲双胍治疗多囊卵巢综合征的临床疗效及对患者性激素、体重指数的影响

doi: 10.16766/j.cnki.issn.1674-4152.004087

1.
浙江中医药大学附属温州市中医院中医妇科, 浙江温州 325000
2.
浙江中医药大学附属温州市中医院肝病科

基金项目:

浙江省中医药科技计划项目 2022ZL674

温州市科技局项目 Y2023235

详细信息

通讯作者:
孙云，E-mail: 78750121@qq.com

中图分类号: R711.75
计量
- 文章访问数: 7
- HTML全文浏览量: 5
- PDF下载量: 1
- 被引次数: 0
出版历程
- 收稿日期: 2024-06-12
- 网络出版日期: 2025-10-25

Clinical efficacy of Yikang Decoction combined with metformin in the treatment of polycystic ovary syndrome and its impact on the levels of sex hormones and body mass index in patients

1.
Gynecology Department of Wenzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang University of Traditional Chinese Medicine, Wenzhou, Zhejiang 325000, China

摘要

摘要: 目的多囊卵巢综合征在育龄女性中较为多发，对患者身心健康均造成了不利影响，本研究采用抑亢汤联合二甲双胍治疗，探究两者联合对患者性激素、体重指数等指标的影响，以期为多囊卵巢综合征临床治疗方案选择提供借鉴。方法选择2022年1月—2024年1月浙江中医药大学附属温州市中医院治疗的102例多囊卵巢综合征患者为研究对象，按照随机数字表法分为对照组(51例)和研究组(51例)。对照组给予常规治疗、二甲双胍治疗，研究组给予常规治疗、二甲双胍、抑亢汤治疗。评估2组中医症候积分(崩漏、月经稀发、面部痤疮、胸肋胀痛)、性激素[促黄体生成激素(LH)、睾酮(T)、促卵泡生成激素(FSH)]、体重指数、糖代谢指标[空腹胰岛素(FINS)、空腹血糖(FPG)、胰岛素抵抗指数(HOMA-IR)]、脂肪因子[脂肪素(Apelin)、丝氨酸蛋白酶抑制剂(Vaspin)]及临床疗效。结果治疗后，研究组中医症候积分、LH、T、体重指数、FINS、FPG、HOMA-IR、Apelin、Vaspin水平均低于对照组，FSH水平高于对照组；研究组总有效率高于对照组[94.12%(48/51) vs. 78.43%(40/51)], 差异有统计学意义(χ²=5.299，P=0.021)。结论抑亢汤联合二甲双胍治疗多囊卵巢综合征患者性激素、体征、糖脂代谢改善及体重指数降低更为明显，且治疗有效率较高。
- 抑亢汤 /
- 二甲双胍 /
- 多囊卵巢综合征 /
- 临床疗效 /
- 性激素 /
- 体重指数
Abstract: Objective Polycystic ovary syndrome (PCOS) is more common in women of childbearing age and has adverse effects on the physical and mental health of patients. This study adopted Yikang Decoction combined with metformin to explore the effects of the combination of the two on the levels of sex hormones, body mass index, and other indicators of patients, so as to provide references for the selection of clinical treatment of PCOS. Methods A total of 102 patients with polycystic ovary syndrome treated in Wenzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medicine University from January 2022 to January 2024 were selected as the study objects. According to the random number table method, they were divided into a control group (n=51) to receive conventional treatment and metformin treatment, and a study group (n=51) to receive conventional treatment, metformin treatment, and Yikang Decoction treatment. To evaluate traditional Chinese medicine (TCM) syndrome points (leakage, menstrual menstruation, facial acne, chest and rib pain), sex hormones luteinizing hormone (LH), testosterone (T), follicle stimulating hormone (FSH), body mass index, glucose metabolism index fasting insulin (FINS), fasting plasma glucose (FPG), homeostasis model assessment of insulin resistance (HOMA-IR), adipokines [aplin peptides (Apelin), visceral adipose-specific serine protease inhibitor (Vaspin)] and clinical efficacy. Results After treatment, the levels of TCM syndrome score, LH, T, body mass index, FINS, FPG, HOMA-IR, Apelin, and Vaspin in the study group were lower than those in the control group, the FSH level in the study group was higher than that in the control group, and the total response rate in the study group was higher than that in the control group [94.12% (48/51) vs. 78.73% (40/51), χ²=5.299, P=0.021]. Conclusion After treatment with Yikang Decoction combined with metformin, the improvement of sex hormones, physical signs, and glucose-lipid metabolism, and the decrease of body mass index were more obvious in PCOS patients, and the treatment efficiency was higher.
- Yikang Decoction /
- Metformin /
- Polycystic ovary syndrome /
- Clinical effect /
- Sex hormone /
- Body mass index

HTML全文

表 1 2组多囊卵巢综合征患者一般资料比较

Table 1. Comparison of general data of PCOS patients between two groups

组别	例数	年龄(x±s，岁)	病程(x±s，年)	腰围(x±s，cm)	臀围(x±s，cm)	婚姻状况[例(%)]
组别	例数	年龄(x±s，岁)	病程(x±s，年)	腰围(x±s，cm)	臀围(x±s，cm)	已婚	未婚
对照组	51	26.14±2.60	2.01±0.36	86.16±10.33	95.06±11.25	37(72.55)	14(27.45)
研究组	51	25.83±2.73	1.96±0.40	85.93±10.45	94.72±11.47	36(70.59)	15(29.41)
统计量		0.587^a	0.664^a	0.112^a	0.151^a	0.048^b
P值		0.558	0.509	0.911	0.880	0.826
注：^a为t值，^b为χ²值。

下载: 导出CSV

表 2 2组多囊卵巢综合征患者中医症候积分比较(x±s，分)

Table 2. Comparison of TCM syndrome scores between two groups of PCOS patients (x±s, points)

组别	例数	崩漏		t值	P值	月经稀发		t值	P值
组别	例数	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
对照组	51	5.01±0.52	3.51±0.33	17.393	＜0.001	5.02±0.55	3.72±0.39	13.769	＜0.001
研究组	51	4.98±0.53	2.12±0.25	34.854	＜0.001	4.96±0.60	2.03±0.22	32.742	＜0.001
统计量		0.289^a	1 423.972^b			0.526^a	1 421.007^b
P值		0.774	＜0.001			0.600	＜0.001

组别	例数	面部痤疮		t值	P值	胸肋胀痛		t值	P值
组别	例数	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
对照组	51	2.01±0.36	1.62±0.25	6.355	＜0.001	2.02±0.39	1.58±0.17	7.386	＜0.001
研究组	51	1.99±0.33	1.07±0.11	18.888	＜0.001	1.99±0.41	1.02±0.12	16.215	＜0.001
统计量		0.293^a	1 584.383^b			0.379^a	1 479.289^b
P值		0.771	＜0.001			0.706	＜0.001
注：^a为t值，^b为F值。

下载: 导出CSV

表 3 2组多囊卵巢综合征患者性激素水平比较(x±s)

Table 3. Comparison of sex hormones between two groups of patients with PCOS (x±s)

组别	例数	LH(U/L)		t值	P值	T(ng/mL)		t值	P值	FSH(U/L)		t值	P值
组别	例数	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
对照组	51	10.99±1.01	6.25±0.81	26.146	＜0.001	1.95±0.17	0.82±0.08	42.951	＜0.001	4.01±0.48	7.23±0.89	22.741	＜0.001
研究组	51	11.03±0.97	4.15±0.58	43.474	＜0.001	2.02±0.15	0.61±0.05	61.426	＜0.001	3.99±0.50	8.36±1.02	27.473	＜0.001
统计量		0.204^a	1 553.052^b			0.630^a	1 576.627^b			0.206^a	1 579.962^b
P值		0.839	＜0.001			0.530	＜0.001			0.837	＜0.001
注：^a为t值，^b为F值。

下载: 导出CSV

表 4 2组多囊卵巢综合征患者体重指数水平比较(x±s)

Table 4. Comparison of body mass index between two groups of patients with PCOS (x±s)

组别	例数	治疗前	治疗后	t值	P值
对照组	51	28.02±1.01	26.89±0.85	6.113	＜0.001
研究组	51	27.95±0.97	24.33±0.69	21.717	＜0.001
统计量		0.357^a	1 672.599^b
P值		0.722	＜0.001
注：^a为t值，^b为F值。

下载: 导出CSV

表 5 2组多囊卵巢综合征患者糖代谢指标水平比较(x±s)

Table 5. Comparison of glucose metabolism indexes between two groups of patients with PCOS (x±s)

组别	例数	FINS(μIU/mL)		t值	P值	FPG(mmol/mL)		t值	P值	HOMA-IR		t值	P值
组别	例数	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
对照组	51	17.79±1.20	13.52±1.11	18.655	＜0.001	6.10±0.62	4.82±0.51	11.386	＜0.001	4.02±0.42	2.54±0.30	20.478	＜0.001
研究组	51	18.10±1.19	10.01±0.98	37.477	＜0.001	5.97±0.61	4.23±0.36	17.543	＜0.001	3.98±0.45	1.92±0.14	31.216	＜0.001
统计量		1.310^a	1 658.949^b			1.067^a	1 579.760^b			0.464^a	1 627.354^b
P值		0.193	＜0.001			0.288	＜0.001			0.644	＜0.001
注：^a为t值，^b为F值。

下载: 导出CSV

表 6 2组多囊卵巢综合征患者脂肪因子水平比较(x±s，pg/mL)

Table 6. Comparison of adipokine levels between two groups of PCOS patients (x±s, pg/mL)

组别	例数	Apelin		t值	P值	Vaspin		t值	P值
组别	例数	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
对照组	51	6.98±0.80	4.12±0.58	20.670	＜0.001	1.97±0.21	0.91±0.13	30.650	＜0.001
研究组	51	7.06±0.76	3.20±0.35	32.945	＜0.001	2.03±0.19	0.72±0.08	45.380	＜0.001
统计量		0.518^a	1 572.599^b			1.513^a	1 628.779^b
P值		0.606	＜0.001			0.133	＜0.001
注：^a为t值，^b为F值。

下载: 导出CSV

表 7 2组多囊卵巢综合征患者总有效率比较[例(%)]

Table 7. Comparison of clinical efficacy between two groups of patients with PCOS [cases (%)]

组别	例数	痊愈	有效	无效	总有效
对照组	51	19(37.25)	21(41.18)	11(21.57)	40(78.43)
研究组	51	28(54.90)	20(39.22)	3(5.88)	48(94.12)
注：2组总有效率比较，χ²=5.299，P=0.021。

下载: 导出CSV

参考文献(22)

[1]	DIVALL S A. Practical considerations for diagnosis and treatment of polycystic ovary syndrome in adolescence-distilling guidelines into clinical practice[J]. Curr Opin Pediatr, 2023, 35(4): 494-499. doi: 10.1097/MOP.0000000000001255
[2]	徐颖, 米海霞, 杨洋. 穴位埋线治疗对多囊卵巢综合征患者代谢和激素水平的影响[J]. 中华全科医学, 2024, 22(4): 665-668. doi: 10.16766/j.cnki.issn.1674-4152.003475 XU Y, MI H X, YANG Y. Effect of acupoint catgut embedding therapy on metabolism and hormone levels in patients with polycystic ovary syndrome[J]. Chinese Journal of General Practice, 2024, 22(4): 665-668. doi: 10.16766/j.cnki.issn.1674-4152.003475
[3]	GARCIA-GOMEZ E, GOMEZ-VIAIS Y I, CRUZ-ARANDA M M, et al. The effect of metformin and carbohydrate-controlled diet on DNA methylation and gene expression in the endometrium of women with polycystic ovary syndrome[J]. Int J Mol Sci, 2023, 24(7): 6857. DOI: 10.3390/ijms24076857.
[4]	梁新新, 林睿. 二甲双胍联合戊酸雌二醇、克罗米芬治疗多囊卵巢综合征所致不孕症对患者胰岛素、胰岛素抵抗指数水平及卵巢排卵功能的影响[J]. 陕西医学杂志, 2023, 52(4): 460-463. LIANG X X, LIN R. Effects of metformin combined with estradiol valerate and clomiphene in treatment of patients with infertility caused by polycystic ovary syndrome on levels of FINS, HOMA-IR and ovarian ovulation function[J]. Shaanxi Medical Journal, 2023, 52(4): 460-463.
[5]	冯玉军, 李蕊, 张华俊. 利拉鲁肽联合二甲双胍对肥胖型多囊卵巢综合征患者性激素、胰岛素抵抗和脂肪细胞因子的影响[J]. 川北医学院学报, 2023, 38(10): 1329-1333. FENG Y J, LI R, ZHANG H J. Effects of liraglutide combined with metformin on sex hormones, insulin resistance and adipocytokines in obese patients with polycystic ovary syndrome[J]. Journal of North Sichuan Medical College, 2023, 38(10): 1329-1333.
[6]	陈丽, 袁世强, 赵敏. 自拟滋阴抑亢汤联合醋酸泼尼松片、阿司匹林改善免疫性不孕妊娠结局的临床效果评价[J]. 中国性科学, 2021, 30(5): 126-129. CHEN L, YUAN S Q, ZHAO M. Clinical evaluation on self-designed Ziyinyikang Decoction combined with prednisone acetate tablet and aspi-rin to improve pregnancy outcome of immune infertility[J]. Chinese Journal of Human Sexuality, 2021, 30(5): 126-129.
[7]	中华医学会妇产科学分会内分泌学组及指南专家组. 多囊卵巢综合征中国诊疗指南[J]. 中华妇产科杂志, 2018, 53(1): 2-6. Chinese Society of Obstetrics and Gynecology Endocrinology Group and guidelines expert group. Chinese diagnosis and treatment guide for polycystic ovary syndrome[J]. Chinese Journal of Obstetrics and Gynecology, 2018, 53(1): 2-6.
[8]	罗颂平, 谈勇. 中医妇科学[M]. 2版. 北京: 人民卫生出版社, 2014: 252-258. LUO S P, TAN Y. Traditional Chinese gynecology[M]. 2nd Ed. Beijing: People's Medical Publishing House, 2014: 252-258.
[9]	中华人民共和国卫生部. 中药新药临床研究指导原则(试行)[M]. 北京: 中国医药科技出版社, 2012: 54-57. Ministry of Health of the People's Republic of China. Guiding Principles for Clinical Research of New Chinese Medicine (Trial)[M]. Beijing: China Medical Science and Technology Press, 2012: 54-57.
[10]	CHEN J Y. Comment on: effects of bariatric surgery on the menstruation and reproductive-related hormones of obese women without polycystic ovary syndrome: a systematic review and meta-analysis[J]. Surg Obes Relat Dis, 2022, 18(2): e7-e8. doi: 10.1016/j.soard.2021.11.007
[11]	JANEZ A, HERMAN R, POREDOS P, et al. Cardiometabolic risk, peripheral arterial disease and cardiovascular events in polycystic ovary syndrome: time to implement systematic screening and update the management[J]. Curr Vasc Pharmacol, 2023, 21(6): 424-432. doi: 10.2174/0115701611269146230920073301
[12]	袁媛. 龙胆泻肝汤联合二甲双胍治疗肝经湿热型多囊卵巢综合征患者的效果及对胰岛素抵抗和血清脂肪因子水平的影响[J]. 中国妇幼保健, 2022, 37(14): 2613-2616. YUAN Y. Effect of Gentian Xergan Decoction combined with metformin in the treatment of patients with damp-heat polycystic ovary syndrome and its influence on insulin resistance and serum adipokine levels[J]. Maternal & Child Health Care of China, 2022, 37(14): 2613-2616.
[13]	朱美文, 岳德永, 曹作增, 等. 加味芎归二陈汤联合西药治疗痰湿型多囊卵巢综合征疗效及对患者糖脂代谢和血清性激素水平的影响[J]. 陕西中医, 2022, 43(4): 442-445. ZHU M W, YUE D Y, CAO Z Z, et al. Therapeutic effect of Jiawei Xionggui Erchen Decoction combined with Western medicine on phlegm-dampness polycystic ovary syndrome and its influence on glucose and lipid metabolism and serum sex hormone levels[J]. Shaanxi Journal of Traditional Chinese Medicine, 2022, 43(4): 442-445.
[14]	徐素君, 雷丽红, 陈敏, 等. 针灸联合抑亢汤治疗多囊卵巢综合征疗效及对卵巢储备功能的影响[J]. 中华中医药学刊, 2020, 38(7): 63-66. XU S J, LEI L H, CHEN M, et al. Effect of acupuncture combinedwith anti-hyperfunction decoction on ovarian reserve in patients with polycystic ovary syndrome[J]. Chinese Archives of Traditional Chinese Medicine, 2020, 38(7): 63-66.
[15]	刘源, 李煜, 吴侠. 血清前蛋白转化酶枯草溶菌素9、分泌型卷曲相关蛋白-4表达与肥胖性多囊卵巢综合征患者性激素、糖脂代谢的相关性[J]. 中国医师进修杂志, 2024, 47(1): 27-32. LIU Y, LI Y, WU X. Correlation between the expression of serum preprotein convertase subtilisin/kexin type 9, secreted frizzled related protein-4 and sex hormone, glucose and lipid metabolism in patients with obese polycystic ovary syndrome[J]. Chinese Journal of Postgraduates of Medicine, 2024, 47(1): 27-32.
[16]	SHAHVEGHAR ASL Z, PARASTOUEI K, ESKANDARI E. The effects of n-acetylcysteine on ovulation and sex hormones profile in women with polycystic ovary syndrome: a systematic review and meta-analysis[J]. Br J Nutr, 2023, 130(2): 202-210. doi: 10.1017/S0007114522003270
[17]	杨婷, 谭姣姣, 杨静. 温针灸联合常规西药对多囊卵巢综合征不孕症患者卵巢功能、妊娠情况和性激素的影响[J]. 河北中医, 2023, 45(9): 1545-1548. YANG T, TAN J J, YANG J. Effect of warming needle moxibustion combined with western medicine on ovarian function, pregnancy and hormones in infertile patients with polycystic ovary syndrome[J]. Hebei Journal of Traditional Chinese Medicine, 2023, 45(9): 1545-1548.
[18]	王丽萍, 方春霞, 付伟平, 等. 减轻体质量对肥胖的多囊卵巢综合征患者体外受精-胚胎移植周期卵巢反应性及妊娠结局的影响[J]. 中国妇幼保健, 2023, 38(4): 679-682. WANG L P, FANG C X, FU W P, et al. The effect of weight loss on ovarian response and clinical outcome in obese patients with polycystic ovary syndrome undergoing IVF treatment[J]. Maternal & Child Health Care of China, 2023, 38(4): 679-682.
[19]	贵小婷, 黄琦, 袁晓英, 等. 多囊卵巢综合征患者血清、卵泡液固醇调节元件结合蛋白1c、富含亮氨酸的α-2-糖蛋白1水平的变化及与胰岛素抵抗的相关性研究[J]. 中华内分泌代谢杂志, 2023, 39(11): 937-943. GUI X T, HUANG Q, YUAN X Y, et al. Correlation of serum and follicular fluid SREBP1c and LRG1 levels with insulin resistance in PCOS patients[J]. Chinese Journal of Endocrinology and Metabolism, 2023, 39(11): 937-943.
[20]	董文超, 朱晶瑜, 相振华, 等. 加减苍附导痰汤联合二甲双胍、炔雌醇环丙孕酮片治疗痰湿型多囊卵巢综合征的疗效及对血清Ghrelin的影响[J]. 广州中医药大学学报, 2022, 39(11): 2545-2553. DONG W C, ZHU J Y, XIANG Z H, et al. Therapeutic effect of modified cang fu daotan decoction combined with metformin and diane-35 for polycystic ovary syndrome of phlegm-damp syndrome type and its effect on serum Ghrelin[J]. Journal of Guangzhou University of Traditional Chinese Medicine, 2022, 39(11): 2545-2553.
[21]	蔡程跃. 复方左炔诺孕酮联合克罗米芬对多囊卵巢综合征患者血清Apelin eNOS表达及胰岛素抵抗的影响[J]. 中国妇幼保健, 2021, 36(23): 5549-5552. CAI C Y. Effects of compound levonorgestrel combined with clomiphene on serum Apelin eNOS expression and insulin resistance in patients with polycystic ovary syndrome[J]. Maternal & Child Health Care of China, 2021, 36(23): 5549-5552.
[22]	欧英霞, 杨盼, 龙玲, 等. 多囊卵巢综合征患者血清IMA、HIF1α、Vaspin、IGF-1水平与性激素、糖脂代谢及胰岛素抵抗的关系研究[J]. 现代生物医学进展, 2021, 21(14): 2773-2777. OU Y X, YANG P, LONG L, et al. Relationship between serum IMA, HIF1α, Vaspin, IGF-1 Levels and sex hormone, glucose and lipid metabolism, insulin resistance in patients with lycystic ovary syndrome[J]. Progress in Modern Biomedicine, 2021, 21(14): 2773-2777.